Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
Abstract Background Infigratinib is a fibroblast growth factor receptor (FGFR)-specifc tyrosine kinase inhibitor indicated for the treatment of patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma. However, few studies have been conducted to evaluated the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-09-01
|
| Series: | Drugs in R&D |
| Online Access: | https://doi.org/10.1007/s40268-023-00439-1 |